Profile data is unavailable for this security.
About the company
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
- Revenue in EUR (TTM)1.77bn
- Net income in EUR360.83m
- Incorporated1996
- Employees5.65k
- LocationQiagen NVHulsterweg 82VENLO 5912 PLNetherlandsNLD
- Phone+31 773556600
- Fax+31 773208409
- Websitehttps://www.qiagen.com/
More ▼
Mergers & acquisitions
| Acquired company | QIAX:GER since announced | Transaction value |
|---|---|---|
| Parse Biosciences Inc | 9.21% | 280.00m |
| GNX Data Systems Inc | 14.75% | 80.00m |
Data delayed at least 15 minutes, as of Feb 06 2026 16:36 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics, Inc. | 87.21m | -751.94m | 7.37bn | 498.00 | -- | -- | -- | 84.45 | -6.31 | -6.31 | 0.7328 | -4.27 | 0.0607 | -- | 85.00 | 175,122.50 | -52.35 | -45.50 | -57.39 | -50.38 | -- | -- | -862.21 | -748.37 | -- | -14.45 | 1.96 | -- | 145.34 | -7.22 | -12.03 | -- | 8.32 | -- |
| Vaxcyte Inc | 0.00 | -657.20m | 7.60bn | 414.00 | -- | 2.42 | -- | -- | -4.84 | -4.84 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -19.53 | -26.00 | -20.51 | -27.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.33 | -- | 151.05 | -- |
| Nuvalent Inc | 0.00 | -381.44m | 7.79bn | 218.00 | -- | 8.63 | -- | -- | -5.32 | -5.32 | 0.00 | 11.70 | 0.00 | -- | -- | 0.00 | -35.18 | -25.32 | -37.61 | -26.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -106.59 | -- | -- | -- |
| Praxis Precision Medicines Inc | 7.46m | -273.04m | 8.38bn | 116.00 | -- | 18.83 | -- | 1,122.36 | -12.90 | -12.90 | 0.3533 | 16.23 | 0.0184 | -- | -- | 64,336.21 | -67.20 | -70.37 | -75.12 | -79.85 | -- | -- | -3,658.53 | -6,809.15 | -- | -- | 0.00 | -- | 249.53 | -- | -48.30 | -- | -- | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -83.48m | 9.04bn | 18.60k | -- | 2.65 | 26.02 | 2.25 | -1.56 | -1.56 | 80.18 | 69.20 | 0.5186 | 8.23 | 5.41 | 216,328.20 | -1.03 | 5.12 | -1.20 | 6.01 | 34.68 | 36.56 | -1.98 | 9.47 | 1.10 | 3.18 | 0.388 | 0.00 | -1.92 | 9.09 | -97.83 | -47.25 | 10.64 | -- |
| Arrowhead Pharmaceuticals Inc | 829.45m | -1.63m | 9.05bn | 711.00 | -- | 18.82 | 167.42 | 10.91 | -0.0644 | -0.0644 | 6.19 | 3.43 | 0.657 | -- | -- | 1,166,594.00 | 2.39 | -25.96 | 2.76 | -30.82 | -- | -- | 3.63 | -76.01 | -- | 1.89 | 0.5528 | -- | 23,258.15 | 56.63 | 99.73 | -- | 13.66 | -- |
| Tempus AI Inc | 1.11bn | -203.88m | 9.33bn | 2.40k | -- | 18.36 | -- | 8.44 | -1.18 | -1.18 | 6.45 | 2.86 | 0.6795 | 9.29 | 5.15 | 460,524.20 | -12.53 | -53.69 | -15.38 | -72.10 | 61.73 | 45.68 | -18.45 | -84.29 | 3.12 | -3.83 | 0.7104 | -- | 30.38 | 62.05 | -180.61 | -- | 5.36 | -- |
| BIO-TECHNE Corp | 1.22bn | 79.96m | 10.30bn | 3.10k | 129.76 | 5.11 | 56.08 | 8.48 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
| Summit Therapeutics Inc | 0.00 | -921.62m | 10.31bn | 159.00 | -- | 53.63 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2583 | 0.00 | -- | -- | 0.00 | -241.08 | -78.31 | -287.72 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| Madrigal Pharmaceuticals Inc | 740.64m | -289.13m | 10.52bn | 528.00 | -- | 16.81 | -- | 14.21 | -13.01 | -13.01 | 33.39 | 27.56 | 0.6082 | 0.9008 | 10.30 | 1,402,727.00 | -23.74 | -68.48 | -30.98 | -85.32 | 95.25 | -- | -39.04 | -876.55 | 3.26 | -- | 0.3519 | -- | -- | -- | -24.69 | -- | 106.52 | -- |
| Qiagen NV | 2.09bn | 424.88m | 10.55bn | 5.65k | 25.66 | 2.94 | 17.05 | 5.05 | 2.00 | 2.00 | 9.80 | 17.45 | 0.3488 | 2.66 | 5.45 | 369,649.60 | 7.09 | 5.89 | 7.77 | 6.96 | 62.97 | 63.60 | 20.33 | 17.13 | 3.31 | -- | 0.3045 | -- | 5.65 | 2.25 | 408.28 | 3.42 | -7.40 | -- |
| ICON PLC | 8.10bn | 599.48m | 11.10bn | 39.80k | 19.65 | 1.19 | 11.23 | 1.37 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Exelixis Inc | 2.29bn | 677.90m | 11.36bn | 1.15k | 17.84 | 5.26 | 16.05 | 4.96 | 2.38 | 2.38 | 8.00 | 8.06 | 0.7913 | 3.19 | 7.90 | 1,994,959.00 | 23.44 | 9.51 | 27.03 | 10.77 | 96.63 | 96.32 | 29.63 | 15.61 | 3.68 | -- | 0.00 | 0.00 | 18.49 | 17.51 | 150.89 | 10.18 | 17.25 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -3.58m | 12.40bn | 12.00 | -- | 2,550.65 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.0098 | 0.00 | -- | -- | 0.00 | -50.50 | -53.93 | -53.75 | -65.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.68 | -- | 5.32 | -- |
| Ionis Pharmaceuticals Inc | 966.96m | -256.34m | 13.52bn | 1.07k | -- | 21.77 | -- | 13.98 | -1.71 | -1.71 | 5.87 | 3.84 | 0.3163 | 0.6054 | 45.47 | 904,542.60 | -8.39 | -11.71 | -10.45 | -13.72 | 98.78 | 98.42 | -26.51 | -44.15 | 2.78 | -- | 0.7414 | -- | -10.48 | -8.88 | -23.92 | -- | 7.94 | -- |
Data as of Feb 06 2026. Currency figures normalised to Qiagen NV's reporting currency: US Dollar USD
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| State Street Global Advisors Ltd.as of 08 Jan 2026 | 129.38k | 0.00% |
| DWS Investment SAas of 08 Jan 2026 | 45.57k | 0.00% |
| Invesco Investment Management Ltd.as of 08 Jan 2026 | 31.63k | 0.00% |
| Global X Management Co. (UK) Ltd.as of 08 Jan 2026 | 19.45k | 0.00% |
| Cathay Securities Investment Trust Co., Ltd.as of 08 Jan 2026 | 14.54k | 0.00% |
| State Street Global Advisors Europe Ltd.as of 08 Jan 2026 | 2.63k | 0.00% |
| TIMEFOLIO Asset Management Co., Ltd.as of 08 Jan 2026 | 2.19k | 0.00% |
| Keyridge Asset Management Ltd.as of 08 Jan 2026 | 1.48k | 0.00% |
| UBS Asset Management (Europe) SAas of 29 Jan 2026 | 1.39k | 0.00% |
| Applied Finance Advisors LLCas of 09 Jan 2026 | 762.00 | 0.00% |
More ▼
Data from 11 Jan 2026 - 30 Jan 2026Source: FactSet Research Systems Inc.
